[Report] Epigenomics Market Research, Trends, Analysis TOC

INTRODUCTIONSTUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- CONTRIBUTION OF THE STUDY AND FOR WHOM
- SCOPE AND FORMAT
- METHODOLOGY
- ANALYST CREDENTIALS
- RELATED BCC PUBLICATIONS
- BCC ONLINE SERVICES
- DISCLAIMER
SUMMARY
- Summary Table:
- GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, THROUGH 2012 ($ MILLIONS)
- Summary Figure:
- GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, 2005-2012 ($ MILLIONS)
OVERVIEW
- INTRODUCTION
- THE NEW PARADIGM OF EPIGENOMICS
Figure 1 EPIGENOMICS: A NEW PARADIGM
- HOW EPIGENOMICS FITS WITHIN THE GENOMICS FIELD
Table 1 GENOMICS PLATFORMS
- ELEMENTS OF THE EPIGENOME COVERED IN THIS REPORT
Table 2 ELEMENTS OF THE EPIGENOME COVERED IN THIS REPORT
- MARKET POTENTIAL OF EPIGENOMICS
Table 3 GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, THROUGH 2012 ($ MILLIONS)
- KEY EPIGENOMICS PRODUCTS
  - RESEARCH TOOLS AND REAGENTS
  - DIAGNOSTICS
  - DRUGS
- DRIVING FORCES FOR GROWTH IN EPIGENOMICS
- IMPORTANCE OF EPIGENETIC TECHNOLOGY
Figure 2 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL DEVELOPMENT
- LIFE CYCLE STATUS OF EPIGENOMICS TECHNOLOGIES
- HISTORICAL BACKGROUND
Table 4 HISTORICAL OVERVIEW OF EPIGENETICS
- THE EPIGENOMICS INDUSTRY
Table 5 EPIGENOMICS INDUSTRY
- THE EPIGENOMICS INDUSTRY (CONTINUED)
EPIGENETIC TECHNOLOGY
- INTRODUCTION
- TWO MAIN EPIGENOMIC ANALYSIS TECHNOLOGIES
Table 6 TWO TYPES OF EPIGENOMIC ANALYSIS TECHNOLOGIES
- STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES
Table 7 STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES
- DNA AND HISTONE ANALYSIS WORKFLOW
- Figure 3 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS
DNA METHYLATION
- METHYLATED CYTOSINE-A FIFTH BASE
- Figure 4 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION
BIOLOGICAL ROLE OF DNA METHYLATION
- Table 8 BIOLOGICAL ROLES OF DNA METHYLATION
- Table 8 (CONTINUED)
  - DNA METHYLTRANSFERASE ENZYMES
  - CPG ISLANDS
Table 9 CPG ISLANDS: SUBJECT TO DNA METHYLATION
- HISTONE METHYLATION AND ACETYLATION
  - HISTONES
Figure 5 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC
- HISTONE ACETYLATION AND METHYLATION ENZYMES
Figure 6 HISTONE ACETYLATION AND METHYLATION ENZYMES
- Histone Acetyl Transferases (HAT Enzymes)
- Histone Deacetylases (HDAC Enzymes)
Table 10 HDAC ENZYMES CLASSES
- Histone Methyltransferases and Demethylases
- INAPPROPRIATE METHYLATION AND ACETYLATION
Table 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION
EPIGENOMIC ANALYSIS TECHNOLOGIES
- ROLE OF EPIGENOMIC RESEARCH TOOLS
- DNA METHYLATION RESEARCH TOOLS
Table 12 DNA METHYLATION ANALYSIS ASSAYS
- DNA METHYLATION ANALYSIS WORKFLOW
Figure 7 METHYLATED DNA ANALYSIS WORKFLOW
- ANALYSIS TYPES BY WORKFLOW
Table 13 EXAMPLES OF DNA METHYLATION ASSAYS
- DNA METHYLATION ANALYSIS: UPSTREAM TECHNOLOGIES
Table 14 COMPARISON OF UPSTREAM EPIGENOMIC RECOGNITION TECHNOLOGIES
- RESTRICTION ENZYME-BASED METHODS
Figure 8 ANALYSIS OF DNA METHYLATION BY RESTRICTION ENZYMES
- BISULFITE-BASED METHODS
- Bisulfite-Based Methods (Continued)
Figure 9 BISULFITE CONVERSION OF DNA
- Analysis of Low Complexity DNA-A Unique Challenge for Bisulfite Methods
- ANTIBODY-BASED METHODS
- CHALLENGE OF HIGH BACKGROUND METHYLATED DNA
- DNA METHYLATION ANALYSIS: DOWNSTREAM TECHNOLOGIES
- GENOME WIDE DNA METHYLATION ANALYSIS
Table 15 DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME RESOLUTION
- GENOME WIDE DNA ... (CONTINUED)
- HIGH THROUGHPUT PLATFORMS
- HISTONE EPIGENOMIC ANALYSIS TECHNOLOGIES
  - CHROMATIN IMMUNOPRECIPITATION
  - CHIP-ON-CHIP
Figure 10 CHIP-ON-CHIP PROCEDURE
Table 16 CHIP ASSAYS
Table 17 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES
MICROARRAYS
- FEATURE DENSITY
Figure 11 MICROARRAY FEATURE DENSITY
- RESOLUTION
Figure 12 MICROARRAY RESOLUTION
- GENOME CONTENT
Table 18 MICROARRAY GENOME CONTENT
Table 19 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS
- SERIAL ANALYSIS OF GENE EXPRESSION
- ANTIBODIES
- ALTERNATIVES TO ANTIBODIES IN UPSTREAM STEP
  - DNA ADENINE METHYLTRANSFERASE IDENTIFICATION (DAM ID)
    - DNA Adenine Methyltransferase ... (Continued)
DNA METHYLATION BIOMARKERS
- FROM ANALYSIS TO BIOMARKERS
- OPPORTUNITIES FOR BIOTECHNOLOGY COMPANIES IN DIAGNOSTICS
- WHAT IS A BIOMARKER?
- DNA METHYLATION AS A CANCER BIOMARKER
  - DNA METHYLATION IN CANCER ETIOLOGY
Table 20 BIOLOGICAL RATIONALE FOR DNA METHYLATION CANCER BIOMARKERS
Table 21 CANCER-RELATED CELL PATHWAYS AND GENES AFFECTED BY HYPER-METHYLATION
- Cell Cycle Control
- Cell Invasion and Adhesion
- DNA Damage Repair
- Growth Factor Response
  - Regulation of Apoptosis
- Hormonal Response
- Cytokine Signaling
Table 22 CANCER-RELATED EPIGENETIC CHANGES
- MOLECULAR BIOMARKER TECHNOLOGY COMPARISON
Table 23 COMPARISON OF KEY CANCER BIOMARKER TECHNOLOGY PLATFORMS
- Occurrence within the Genome
- Inheritance in Progenitor Cells
- DNA Base Mutation
- Binary Signal
- Presence of Background Signal
- Stable Change in Biomarker Status
- Stability of Sample Material
- Detection of First Hit
- Occurrence in Early or Pre-Cancers
- Tissue Sample Range
- Test Complexity
ASSESSMENT OF DNA METHYLATION BIOMARKER COMPETITIVE POSITION
EPIGENETIC BIOMARKER CANCER GENES
Table 24 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR CANCERS
- EPIGENETIC BIOMARKERS FOR NON-CANCER DISEASES
Table 25 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC AND CARDIOVASCULAR DISORDERS
- BIOMARKER DISCOVERY PROCESS
- METHYLATION BIOMARKER DISCOVERY TECHNOLOGIES
Table 26 DNA METHYLATION ANALYSIS TECHNOLOGIES IN BIOMARKER DISCOVERY
Table 26 (CONTINUED)
- GENOME-WIDE SCANNING TO HUNT FOR BIOMARKERS
- LARGE SCALE REGIONAL EPIGENOMICS PROJECTS
Table 27 REGIONAL EPIGENOMICS INITIATIVES
Table 27 (CONTINUED)
- EUROPE
- UNITED STATES
- ASIA
- HUMAN EPIGENOME PROJECT WILL AID IN THE DISCOVERY OF NEW METHYLATION MARKERS
Table 28 METHYL VARIABLE POSITIONS - MVPS
Table 29 HUMAN EPIGENOME PROJECT: METHYL VARIABLE POSITION ANALYSIS OBJECTIVES
- CASE STUDY: FROM RESEARCH TOOLS TO BIOMARKERS
- CASE STUDY (CONTINUED)
- DEVELOPMENT STAGES FOR AN IN VITRO DIAGNOSTIC
- PHASE 1: BIOMARKER DISCOVERY
- PHASE 2: BIOMARKER VALIDATION
- PHASE 3: FORMAL KIT DEVELOPMENT
- PHASE 4: CLINICAL VALIDATION
TYPES OF CANCER METHYLATION MARKERS
FUTURE STATUS OF DNA METHYLATION BIOMARKERS
Table 30 TECHNICAL HURDLES FOR DEVELOPMENT OF METHYLATION EPIGENETIC CANCER BIOMARKERS
EPIGENETIC CANCER THERAPIES
- INTRODUCTION
- EPIGENETICS IN TUMORIGENESIS
- EPIGENETIC DRUG TARGETS
Table 31 EPIGENETIC GENES ALTERED IN HUMAN CANCERS
Table 31 (CONTINUED)
- HISTONE METHYLATION AND ACETYLATION ENZYME DRUG TARGETS
Figure 13 HISTONE DEACETYLASE REACTION
Table 32 STATUS OF EPIGENETIC ENZYMES THAT TARGET HISTONES
- HISTONE DEACETYLACE INHIBITORS
- HDAC ENZYMES AS DRUG TARGETS
- HDAC INHIBITOR DRUG CLASSES
Table 33 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY
- HYDROXAMATES
Figure 14 TRICHOSTATIN A, A HYDROXAMATE CLASS HDAC INHIBITOR
- ALIPHATIC ACIDS
Figure 15 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS HDAC INHIBITOR
- CYCLIC TETRAPEPTIDES
Figure 16 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC INHIBITOR
- BENZAMIDES
Table 34 MS-275, A BENZAMIDE CLASS HDAC INHIBITOR
- KEY HDAC INHIBITOR TECHNOLOGY TRENDS
Table 35 KEY HDAC INHIBITOR DRUG TRENDS
- ENZYME SELECTIVITY
  - Enzyme Selectivity (Continued)
Table 36 HDAC INHIBITOR CLASS I AND II SELECTIVITY (IC50 RATIO)
- POTENCY
- IMPROVEMENTS IN DRUG-LIKE PROPERTIES
SELECTIVE HDAC COMPOUNDS CAN PROVIDE COMPETITIVE ADVANTAGE
Figure 17 DISEASE HDAC ISOFORM PROFILE
- CHEMICAL DESIGN IS THE KEY TO SELECTIVITY
Figure 18 STRUCTURAL COMPONENTS MOTIFS OF HDAC INHIBITORS
- HDAC INHIBITORS IN COMBINATION THERAPIES
  - HDAC INHIBITORS IN ... (CONTINUED)
Table 37 HDAC INHIBITOR DRUG COMPANIONS
- HDAC INHIBITORS IN ... (CONTINUED)
HDAC INHIBITORS AS THERAPIES FOR NON-CANCER DISEASES
- CARDIAC DISEASE
- DERMATOLOGICAL DISORDERS
- PARASITIC DISEASES
- NEURODEGENERATIVE DISEASES
- DIABETES
- INFLAMMATORY DISEASES
DNA METHYLTRANSFERASE INHIBITORS (DNMT)
Figure 19 LEAD DNMT INHIBITOR COMPOUNDS
- NUCLEOSIDE ANALOGUES
Figure 20 DNMT INHIBITORS AND MODE OF ACTION
- NON-NUCLEOSIDE ANALOGUES
  - ANTISENSE OLIGONUCLEOTIDES
FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT
Table 38 FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT
EPIGENETICS ASSISTED REPRODUCTIVE TECHNOLOGIES
- SOMATIC CELL NUCLEAR TRANSFER
Figure 21 SOMATIC CELL NUCLEAR TRANSFER
Table 39 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL NUCLEAR TRANSFER
Table 40 EPIGENETIC ALTERATIONS IN ASSISTED REPRODUCTIVE DISORDERS
- APPLICATIONS OF EPIGENOMICS IN CLONING
  - REPROGRAMMING FACTORS
Figure 22 EPIGENETIC PROGRAMMING OF STEM CELLS
- CELLULAR IDENTIFICATION AND QUALITY CONTROL ASSAYS
  - Cellular Identification ... (Continued)
MARKET GROWTH DRIVING FORCES
- INTRODUCTION
Table 41 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO EPIGENETICS
- KEY GROWTH DRIVERS
Table 42 PRIMARY FORCES DRIVING EPIGENOMICS PRODUCTS GROWTH
- DEVELOPMENT OF NOVEL EPIGENOMICS RESEARCH TOOLS
- CREATION OF EPIGENETIC MAPS
- SCOPE OF EPIGENETIC ANALYSIS
- NEED FOR EARLY CANCER DETECTION
- NEED FOR BETTER CANCER THERAPIES
- GROWTH IN LIFE SCIENCE RESEARCH BUDGETS
- PERSONALIZED MEDICINE TRENDS
- RESEARCH IN EPIGENETIC PROCESSES
EPIGENOMIC RESEARCH TOOLS MARKETS
- PRODUCTS WITHIN RESEARCH TOOLS
  - EPIGENOMIC KITS
  - REAGENTS
  - MICROARRAYS
- GLOBAL SALES BY TECHNOLOGY
Table 43 GLOBAL MARKET FORECAST FOR EPIGENOMICS RESEARCH TOOL KITS BY TYPE THROUGH 2012 ($ MILLION)
- GLOBAL SALES BY PRODUCT
Table 44 GLOBAL MARKET FORECAST FOR EPIGENOMIC ANALYSIS RESEARCH TOOLS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- EPIGENOMIC KIT SALES BY TECHNOLOGY
Table 45 GLOBAL MARKET FORECAST FOR EPIGENETIC ANALYSIS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- DNA METHYLATION ANALYSIS KIT MARKET
  - DNA METHYLATION ... (CONTINUED)
Table 46 GLOBAL MARKET FORECAST FOR DNA METHYLATION RESEARCH TOOL KITS BY ANALYSIS OBJECTIVE THROUGH 2012 ($ MILLIONS)
Table 47 GLOBAL MARKET FORECAST FOR DNA METHYLATION RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
Table 48 GLOBAL MARKET FORECAST FOR DNA METHYLATION SINGLE LOCI RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
Table 49 GLOBAL MARKET FORECAST FOR DNA METHYLATION GENOME-WIDE RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- HISTONE ANALYSIS KIT MARKET
Table 50 GLOBAL MARKET FORECAST FOR VALUE OF HISTONE ANALYSIS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- MICROARRAY MARKET
  - MICROARRAYS AS DOWNSTREAM ANALYSIS TOOL
    - Microarray Differentiation
Figure 23 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF EPIGENETICS ASSAYS
Table 51 MICROARRAY PROBES
- Microarray ... (Continued)
  - MICROARRAY ANALYSIS PLATFORMS IN THE CLINIC
Table 52 CLINICAL STATUS OF MICROARRAY PLATFORMS
- Microarray Analysis ... (Continued)
  - FUTURE MARKET POSITION OF MICROARRAYS
  - EPIGENOMIC MICROARRAY MARKET
Table 53 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS BY MARKET THROUGH 2012 ($ MILLIONS)
Table 54 GLOBAL VALUE OF EPIGENOMIC RESEARCH TOOLS MICROARRAYS BY ANALYSIS THROUGH 2012 ($ MILLIONS)
Table 55 GLOBAL VALUE OF DIAGNOSTIC MICROARRAYS BY MARKET THROUGH 2012 ($ MILLIONS)
- REAGENTS MARKET
Table 56 GLOBAL VALUE OF EPIGENOMIC REAGENTS BY MARKET THROUGH 2012 ($ MILLIONS)
Table 57 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC REAGENTS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- REAGENTS MARKET (CONTINUED)
EPIGENETIC BIOMARKER AND DIAGNOSTICS MARKETS
- OVERVIEW OF CANCER DIAGNOSTICS MARKET
Table 58 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS MARKETS BY SEGMENT THROUGH 2012 ($ MILLIONS)
- CANCER MOLECULAR DIAGNOSTICS GROWTH DRIVERS
Table 59 TARGETED THERAPY CANCER DRUG COMPOUNDS IN DEVELOPMENT
- METHYLATION BIOMARKERS CLINICAL DEVELOPMENT STATUS
Table 60 DEVELOPMENT STATUS OF SELECTED METHYLATION BIOMARKERS BY CANCER TYPE
- CANCER DIAGNOSTIC MARKET SEGMENTS
- ATTRACTIVE CANCER INDICATIONS FOR SCREENING MARKETS
Figure 24 CANCER SCREENING OPPORTUNITY MATRIX FOR EPIGENETIC TESTS IN DEVELOPMENT
Figure 25 NEW EPIGENETIC SCREENING PARADIGM
- SENSITIVITY AND SPECIFICITY
Figure 26 SENSITIVITY AND SPECIFICITY
- STATUS OF DIAGNOSTICS TESTS FOR SELECTED CANCER INDICATIONS
  - COLORECTAL CANCER
- Colorectal Cancer Screening Tests
Table 61 CURRENT SCREENING AND DIAGNOSTIC TESTS FOR COLORECTAL CANCER
- DNA-based Colorectal Screening Tests
- Epigenetics-based Colorectal Screening Tests
Table 62 ACCURACY OF EXISTING COLORECTAL SCREENING TESTS
- Colorectal Cancer Non-screening Tests
- BLADDER CANCER
- BREAST CANCER
  - Screening for Breast Cancer
  - Relapse Risk Prediction
  - Therapy Prediction
- PROSTATE CANCER
- LUNG CANCER
- OVARIAN CANCER
Table 63 OVARIAN CANCER POTENTIAL SCREENING TESTS
- CERVICAL CANCER
- PANCREATIC CANCER
- GASTRIC CANCER
- PEDIATRIC CANCERS
PERSONALIZED TREATMENT EPIGENETIC-BASED TESTS
KEY CLINICAL REQUIREMENTS FOR AN EPIGENETIC-BASED DIAGNOSTICS TEST
Table 64 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC KIT
- AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTIC TESTS
Table 65 GLOBAL 2007 POTENTIAL AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTIC TEST KITS BY MARKET SEGMENT ($ MILLIONS)
- AVAILABLE MARKET FOR ... (CONTINUED)
Table 66 GLOBAL 2007 POTENTIAL AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTICS TEST KITS BY INDICATION ($ MILLIONS)
Table 67 CANCER INCIDENCE AND ESTIMATED TREATMENT DECISIONS, 2006
Table 67 (CONTINUED)
Table 68 BREAST CANCER DIAGNOSTICS PRODUCT SEGMENTS
- AGING POPULATIONS CONTRIBUTE TO DIAGNOSTICS MARKET POTENTIAL
Table 69 PROJECTED INCREASE IN AGE 65+ POPULATION BY REGION
- DNA METHYLATION DIAGNOSTICS PIPELINE
Table 70 PIPELINE FOR DNA METHYLATION DIAGNOSTICS TESTS
Table 70 (CONTINUED)
- SCREENING TESTS
  - Prostate Cancer Screening Tests
  - Colorectal Cancer Screening Tests
  - Breast Cancer Screening Tests
  - Lung Cancer Screening Tests
  - Bladder Cancer Screening Tests
- MONITORING, CLASSIFICATION, AND PHARMACODIAGNOSTIC TESTS
  - Breast Cancer Classification Tests
  - Prostate Cancer Diagnostics Tests
  - Bladder Cancer Monitoring Tests.
  - Other Non-Screening Tests
- EPIGENETICS BASED DIAGNOSTICS KITS MARKET SIZE
Table 71 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY MARKET THROUGH 2012 ($ MILLIONS)
Table 72 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY INDICATION THROUGH 2012 ($ MILLIONS)
Table 73 2012 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY INDICATION AND SEGMENT ($ MILLIONS)
- EPIGENETIC DIAGNOSTICS KITS MARKET BY TECHNOLOGY
Table 74 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- EPIGENETIC DIAGNOSTICS ... (CONTINUED)
MARKETS FOR EPIGENETIC DRUGS
- OVERVIEW
- THE CANCER DRUG MARKET
Table 75 GLOBAL MARKET FORECAST FOR SELECTED CANCER DRUGS BY, THROUGH 2012 ($ MILLIONS)
- TARGETED THERAPEUTICS
- CANCER DRUG MARKET GROWTH DRIVING FORCES
  - CANCER DRUG ... (CONTINUED)
- EPIGENETIC-BASED DRUGS AS CANCER THERAPIES
- PROOF OF PRINCIPLE OF EPIGENETIC DRUGS ESTABLISHED
- EPIGENETIC THERAPIES BEYOND CANCER
- EPIGENETIC DRUG MARKET FORECAST
Table 76 GLOBAL MARKET FORECAST FOR EPIGENETIC DRUGS BY INDICATION, THROUGH 2012 ($ MILLIONS)
Table 77 GLOBAL MARKET FORECAST FOR EPIGENETIC DRUGS BY CLASS, THROUGH 2012 ($ MILLIONS)
- INITIAL FOCUS ON HEMATOLOGICAL CANCERS
Table 78 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES
- MARKET SIZE FOR HEMATOLOGICAL CANCER DRUGS
Table 79 GLOBAL MARKET FORECAST OF HEMATOLOGICAL CANCER DRUGS BY INDICATION THROUGH 2012 ($ MILLIONS)
Table 80 COMPARISON OF THREE NEW MDS DRUGS
- MARKET SIZE ... (CONTINUED)
HDAC INHIBITORS MARKETS
- STRATEGIC OPPORTUNITIES IN HDAC INHIBITORS
Table 81 SUMMARY OF HDAC INHIBITOR STRATEGIC OPPORTUNITIES FOR CANCER TREATMENT
- HDAC INHIBITORS IN DEVELOPMENT AND CLINICAL TRIALS
Table 82 HDAC INHIBITOR DRUG CANDIDATES IN CLINICAL TRIALS
- Zolinza
- PXD-101
Table 83 PXD-101 CLINICAL TRIALS STATUS
- NVP-LAQ824
- Bacacea, Avugane, Savacol
- Romidepsin
Table 84 ROMIDEPSIN CLINICAL TRIALS STATUS
- MS-275
- CI 994
- MGCD0103
Table 85 MBCD0103 INHIBITS SELECTED HDAC ENZYMES
- PCI-24781
- SRT-501
HDAC INHIBITOR DRUG MARKET SIZE BY INDICATION
Table 86 GLOBAL MARKET FORECAST FOR HDAC INHIBITOR DRUGS BY INDICATION, THROUGH 2012 ($ MILLIONS)
- HDAC INHIBITOR MARKET SIZE BY TECHNOLOGY
Table 87 GLOBAL VALUE OF HDAC INHIBITOR DRUGS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- DNMT INHIBITORS MARKET
  - DNMT INHIBITORS IN CLINICAL TRIALS
Table 88 DNMT INHIBITORS IN CLINICAL TRIALS AND UNDER DEVELOPMENT
Table 88 (CONTINUED)
- Nucleoside Analogues
- 5-azacytidine (Vidaza)
- 5-aza-2' -deoxycitidine (Decitabine, Dacogen)
- Zebularine
- DHAC (Dihydro-5-azacytidine)
- Non-Nucleoside Analogues
- MG98
- Hydralazine
- Preclinical Non-Nucleosides
FDA-APPROVED DNMT INHIBITORS
Table 89 FDA APPROVED DNMT INHIBITOR DRUGS
- MARKET SIZE FOR DNMT INHIBITORS
Table 90 GLOBAL VALUE OF DNMT INHIBITOR DRUGS BY INDICATION THROUGH 2012 ($ MILLIONS)
Table 91 GLOBAL VALUE OF DNMT INHIBITOR DRUGS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- ALTERNATIVE DEMETHYLATION THERAPEUTIC APPROACHES
- CLONING AND TISSUE ENGINEERING MARKETS
Table 92 GLOBAL VALUE OF CLONING AND TISSUE ENGINEERING EPIGENETIC KITS THROUGH 2012 ($ MILLIONS)
COMPETITIVE DYNAMICS
- RESEARCH TOOLS
Table 93 EPIGENOMIC RESEARCH TOOLS SUPPLIERS
- DIAGNOSTICS
Table 94 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY EPIGENETICS DIAGNOSTICS FIRMS
Table 94 (CONTINUED)
Table 95 COMPETITIVE LANDSCAPE FOR MOLECULAR DIAGNOSTICS TECHNOLOGIES
- EPIGENETIC DRUGS
Table 96 COMPETITIVE LANDSCAPE FOR EPIGENETIC DRUG COMPANIES
PATENTS
- RESEARCH TOOLS
Table 97 PATENTS AND PATENT APPLICATION STATUS OF EPIGENOMICS AG RESEARCH TOOLS
- BIOMARKERS AND DIAGNOSTICS
Table 98 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES
- PHARMACEUTICALS
Table 99 HDAC INHIBITOR PATENT CLAIMS: 2004-2006
Table 99 (CONTINUED)
COMPANY PROFILES
- ABBOTT LABORATORIES
- ABCAM PLC.
- ACTIVE MOTIF
- AFFYMETRIX
- AGILENT TECHNOLOGIES, INC.
- APPLIED BIOSYSTEMS
- AVIVA SYSTEMS BIOLOGY
- BAYER AG
- BIOSERVE BIOTECHNOLOGIES, LTD.
- BIOVISION
- CELLARTIS AB
- CELLCENTRIC LTD.
- CHIPSCREEN BIOSCIENCES LTD.
- CHROMA THERAPEUTICS
- CURAGEN
Table 100 CURAGEN STRATEGIC ALLIANCES
- EPIGENOMICS AG
  - EPIGENOMICS AG (CONTINUED)
- EPIGENTEK
- EPIONTIS GMBH
- ELIXIR PHARMACEUTICALS, INC.
- ENTREMED, INC.
- ENVIVO PHARMACEUTICALS
- ES CELL INTERNATIONAL PTE LTD
- EXONHIT THERAPEUTICS SA
- F. HOFFMANN-LA ROCHE, LTD.
- GENPATHWAY, INC.
- GILEAD SCIENCES (MYOGEN)
- GLOUCESTER PHARMACEUTICALS
- HUYA BIOSCIENCE INTERNATIONAL
- ILLUMINA, INC.
- KALYPSYS, INC.
- KARUS THERAPEUTIC LTD
- LEO PHARMA
- MERCK & CO. INC.
- METHYLGENE
Table 101 METHYLGENE EPIGENETIC PRODUCT PIPELINE
- MGI PHARMA, INC.
  - MGI PHARMA, INC. (CONTINUED)
- MILLIPORE (CHEMICON/UPSTATE)
- NIMBLEGEN SYSTEMS, INC.
- NOVARTIS
  - ONCOMETHYLOME SCIENCES S.A.
    - Biomarker Identification and Development Partners
    - Kit Development, Regulatory Review, and Mass Market of Kits
- ORION GENOMICS
  - ORION GENOMICS (CONTINUED)
- PANOMICS, INC.
- PHARMACYCLICS
- PHARMION CORPORATION
Table 102 PHARMION EPIGENETIC DRUG COMBINATION THERAPIES IN CLINICAL TRIALS
Table 103 POTENTIAL PHARMION INTRA-PORTFOLIO DRUG COMBINATIONS
- QUIAGEN GMBH
- RUBICON GENOMICS
- S*BIO PTE LTD1
- SCHERING AG
- SCHERING PLOUGH CORPORATION
- SEQUENOM
- SEQWRIGHT
- SIRTRIS PHARMACEUTICALS
- TAIHO PHARMACEUTICALS
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- TOPOTARGET A/S
Table 104 TOPOTARGET' S HDAC INHIBITOR PATENT PORTFOLIO
Table104 (CONTINUED)
- VERIDEX LLC
- ZYMO RESEARCH
LIST OF TABLES
- Summary Table:
- GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, THROUGH 2012 ($ MILLIONS)
- Table 1 GENOMICS PLATFORMS
- Table 2 ELEMENTS OF THE EPIGENOME COVERED IN THIS REPORT
- Table 3 GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, THROUGH 2012 ($ MILLIONS)
- Table 4 HISTORICAL OVERVIEW OF EPIGENETICS
- Table 5 EPIGENOMICS INDUSTRY
- Table 6 TWO TYPES OF EPIGENOMIC ANALYSIS TECHNOLOGIES
- Table 7 STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES
- Table 8 BIOLOGICAL ROLES OF DNA METHYLATION
- Table 9 CPG ISLANDS: SUBJECT TO DNA METHYLATION
- Table 10 HDAC ENZYMES CLASSES
- Table 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION
- Table 12 DNA METHYLATION ANALYSIS ASSAYS
- Table 13 EXAMPLES OF DNA METHYLATION ASSAYS
- Table 14 COMPARISON OF UPSTREAM EPIGENOMIC RECOGNITION TECHNOLOGIES
- Table 15 DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME RESOLUTION
- Table 16 CHIP ASSAYS
- Table 17 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES
- Table 18 MICROARRAY GENOME CONTENT
- Table 19 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS
- Table 20 BIOLOGICAL RATIONALE FOR DNA METHYLATION
- CANCER BIOMARKERS
- Table 21 CANCER-RELATED CELL PATHWAYS AND GENES AFFECTED BY HYPER-METHYLATION
- Table 22 CANCER-RELATED EPIGENETIC CHANGES
- Table 23 COMPARISON OF KEY CANCER BIOMARKER TECHNOLOGY PLATFORMS
- Table 24 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR CANCERS
- Table 25 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC AND CARDIOVASCULAR DISORDERS
- Table 26 DNA METHYLATION ANALYSIS TECHNOLOGIES IN BIOMARKER DISCOVERY
- Table 27 REGIONAL EPIGENOMICS INITIATIVES
- Table 28 METHYL VARIABLE POSITIONS - MVPS
- Table 29 HUMAN EPIGENOME PROJECT: METHYL VARIABLE POSITION ANALYSIS OBJECTIVES
- Table 30 TECHNICAL HURDLES FOR DEVELOPMENT OF METHYLATION EPIGENETIC CANCER BIOMARKERS
- Table 31 EPIGENETIC GENES ALTERED IN HUMAN CANCERS
- Table 32 STATUS OF EPIGENETIC ENZYMES THAT TARGET HISTONES
- Table 33 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY
- Table 34 MS-275, A BENZAMIDE CLASS HDAC INHIBITOR
- Table 35 KEY HDAC INHIBITOR DRUG TRENDS
- Table 36 HDAC INHIBITOR CLASS I AND II SELECTIVITY (IC50 RATIO)
- Table 37 HDAC INHIBITOR DRUG COMPANIONS
- Table 38 FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT
- Table 39 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL NUCLEAR TRANSFER
- Table 40 EPIGENETIC ALTERATIONS IN ASSISTED REPRODUCTIVE DISORDERS
- Table 41 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO EPIGENETICS
- Table 42 PRIMARY FORCES DRIVING EPIGENOMICS PRODUCTS GROWTH
- Table 43 GLOBAL MARKET FORECAST FOR EPIGENOMICS RESEARCH TOOL KITS BY TYPE THROUGH 2012 ($ MILLION)
- Table 44 GLOBAL MARKET FORECAST FOR EPIGENOMIC ANALYSIS RESEARCH TOOLS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 45 GLOBAL MARKET FORECAST FOR EPIGENETIC ANALYSIS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 46 GLOBAL MARKET FORECAST FOR DNA METHYLATION RESEARCH TOOL KITS BY ANALYSIS OBJECTIVE THROUGH 2012 ($ MILLIONS)
- Table 47 GLOBAL MARKET FORECAST FOR DNA METHYLATION RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 48 GLOBAL MARKET FORECAST FOR DNA METHYLATION SINGLE LOCI RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 49 GLOBAL MARKET FORECAST FOR DNA METHYLATION GENOME-WIDE RESEARCH TOOLS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 50 GLOBAL MARKET FORECAST FOR VALUE OF HISTONE ANALYSIS KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 51 MICROARRAY PROBES
- Table 52 CLINICAL STATUS OF MICROARRAY PLATFORMS
- Table 53 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS BY MARKET THROUGH 2012 ($ MILLIONS)
- Table 54 GLOBAL VALUE OF EPIGENOMIC RESEARCH TOOLS MICROARRAYS BY ANALYSIS THROUGH 2012 ($ MILLIONS)
- Table 55 GLOBAL VALUE OF DIAGNOSTIC MICROARRAYS BY MARKET THROUGH 2012 ($ MILLIONS)
- Table 56 GLOBAL VALUE OF EPIGENOMIC REAGENTS BY MARKET THROUGH 2012 ($ MILLIONS)
- Table 57 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC REAGENTS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 58 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS MARKETS BY SEGMENT THROUGH 2012 ($ MILLIONS)
- Table 59 TARGETED THERAPY CANCER DRUG COMPOUNDS IN DEVELOPMENT
- Table 60 DEVELOPMENT STATUS OF SELECTED METHYLATION BIOMARKERS BY CANCER TYPE
- Table 61 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER
- Table 62 ACCURACY OF EXISTING COLORECTAL SCREENING TESTS
- Table 63 OVARIAN CANCER POTENTIAL SCREENING TESTS
- Table 64 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC KIT
- Table 65 GLOBAL 2007 POTENTIAL AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTIC TEST KITS BY MARKET SEGMENT ($ MILLIONS)
- Table 66 GLOBAL 2007 POTENTIAL AVAILABLE MARKET FOR CANCER MOLECULAR DIAGNOSTICS TEST KITS BY INDICATION ($ MILLIONS)
- Table 67 CANCER INCIDENCE AND ESTIMATED TREATMENT DECISIONS, 2006
- Table 68 BREAST CANCER DIAGNOSTICS PRODUCT SEGMENTS
- Table 69 PROJECTED INCREASE IN AGE 65+ POPULATION BY REGION
- Table 70 PIPELINE FOR DNA METHYLATION DIAGNOSTICS TESTS
- Table 71 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY MARKET THROUGH 2012 ($ MILLIONS)
- Table 72 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY INDICATION THROUGH 2012 ($ MILLIONS)
- Table 73 2012 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY INDICATION AND SEGMENT ($ MILLIONS)
- Table 74 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC KITS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 75 GLOBAL MARKET FORECAST FOR SELECTED CANCER DRUGS BY, THROUGH 2012 ($ MILLIONS)
- Table 76 GLOBAL MARKET FORECAST FOR EPIGENETIC DRUGS BY INDICATION, THROUGH 2012 ($ MILLIONS)
- Table 77 GLOBAL MARKET FORECAST FOR EPIGENETIC DRUGS BY CLASS, THROUGH 2012 ($ MILLIONS)
- Table 78 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES
- Table 79 GLOBAL MARKET FORECAST OF HEMATOLOGICAL CANCER DRUGS BY INDICATION THROUGH 2012 ($ MILLIONS)
- Table 80 COMPARISON OF THREE NEW MDS DRUGS
- Table 81 SUMMARY OF HDAC INHIBITOR STRATEGIC OPPORTUNITIES FOR CANCER TREATMENT
- Table 82 HDAC INHIBITOR DRUG CANDIDATES IN CLINICAL TRIALS
- Table 83 PXD-101 CLINICAL TRIALS STATUS
- Table 84 ROMIDEPSIN CLINICAL TRIALS STATUS
- Table 85 MBCD0103 INHIBITS SELECTED HDAC ENZYMES
- Table 86 GLOBAL MARKET FORECAST FOR HDAC INHIBITOR DRUGS BY INDICATION, THROUGH 2012 ($ MILLIONS)
- Table 87 GLOBAL VALUE OF HDAC INHIBITOR DRUGS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 88 DNMT INHIBITORS IN CLINICAL TRIALS AND UNDER DEVELOPMENT
- Table 89 FDA APPROVED DNMT INHIBITOR DRUGS
- Table 90 GLOBAL VALUE OF DNMT INHIBITOR DRUGS BY INDICATION THROUGH 2012 ($ MILLIONS)
- Table 91 GLOBAL VALUE OF DNMT INHIBITOR DRUGS BY TECHNOLOGY THROUGH 2012 ($ MILLIONS)
- Table 92 GLOBAL VALUE OF CLONING AND TISSUE ENGINEERING EPIGENETIC KITS THROUGH 2012 ($ MILLIONS)
- Table 93 EPIGENOMIC RESEARCH TOOLS SUPPLIERS
- Table 94 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY EPIGENETICS DIAGNOSTICS FIRMS
- Table 95 COMPETITIVE LANDSCAPE FOR MOLECULAR DIAGNOSTICS TECHNOLOGIES
- Table 96 COMPETITIVE LANDSCAPE FOR EPIGENETIC DRUG COMPANIES
- Table 97 PATENTS AND PATENT APPLICATION STATUS OF EPIGENOMICS AG RESEARCH TOOLS
- Table 98 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES
- Table 99 HDAC INHIBITOR PATENT CLAIMS: 2004-2006
- Table 100 CURAGEN STRATEGIC ALLIANCES
- Table 101 METHYLGENE EPIGENETIC PRODUCT PIPELINE
- Table 102 PHARMION EPIGENETIC DRUG COMBINATION THERAPIES IN CLINICAL TRIALS
- Table 103 POTENTIAL PHARMION INTRA-PORTFOLIO DRUG COMBINATIONS
- Table 104 TOPOTARGET' S HDAC INHIBITOR PATENT PORTFOLIO
LIST OF FIGURES
- Summary Figure:
- GLOBAL VALUE OF EPIGENOMICS PRODUCTS BY MARKET SEGMENT, 2005-2012 ($ MILLIONS)
- Figure 1 EPIGENOMICS: A NEW PARADIGM
- Figure 2 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL DEVELOPMENT
- Figure 3 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS
- Figure 4 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION
- Figure 5 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC
- Figure 6 HISTONE ACETYLATION AND METHYLATION ENZYMES
- Figure 7 METHYLATED DNA ANALYSIS WORKFLOW
- Figure 8 ANALYSIS OF DNA METHYLATION BY RESTRICTION ENZYMES
- Figure 9 BISULFITE CONVERSION OF DNA
- Figure 10 CHIP-ON-CHIP PROCEDURE
- Figure 11 MICROARRAY FEATURE DENSITY
- Figure 12 MICROARRAY RESOLUTION
- Figure 13 HISTONE DEACETYLASE REACTION
- Figure 14 TRICHOSTATIN A, A HYDROXAMATE CLASS HDAC INHIBITOR
- Figure 15 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS HDAC INHIBITOR
- Figure 16 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC INHIBITOR
- Figure 17 DISEASE HDAC ISOFORM PROFILE
- Figure 18 STRUCTURAL COMPONENTS MOTIFS OF HDAC INHIBITORS
- Figure 19 LEAD DNMT INHIBITOR COMPOUNDS
- Figure 20 DNMT INHIBITORS AND MODE OF ACTION
- Figure 21 SOMATIC CELL NUCLEAR TRANSFER
- Figure 22 EPIGENETIC PROGRAMMING OF STEM CELLS
- Figure 23 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF EPIGENETICS ASSAYS
- Figure 24 CANCER SCREENING OPPORTUNITY MATRIX FOR EPIGENETIC TESTS IN DEVELOPMENT
- Figure 25 NEW EPIGENETIC SCREENING PARADIGM
- Figure 26 SENSITIVITY AND SPECIFICITY

Epigenomics: Emerging Opportunities in Biomarkets, Diagnostics and Therapeutics

Table of Contents